The US firm, an affiliate of Ionis Pharmaceuticals, seeks to bring transformative medicines to patients by driving clinical program execution, understanding patient need and commecializing globally.

Akcea has a robust portfolio of development-stage drugs covering multiple targets and diseases using advanced RNA-targeted antisense therapeutics.